19 citations
,
August 1999 in “European journal of endocrinology” The study concluded that testing hormone levels after stimulation is not reliable for identifying carriers of 21-hydroxylase deficiency; genetic testing is necessary.
8 citations
,
March 2012 in “Mass spectrometry letters” The S9 fraction with GC-IDMS is effective for measuring 5α-reductase activity.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
10 citations
,
January 2013 in “Journal of skin cancer” PKC ε increases hair follicle stem cell turnover and may raise skin cancer risk.
37 citations
,
May 2007 in “International Journal of Pharmaceutics” PPCM microspheres allow controlled finasteride release over 24 hours.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
5 citations
,
January 2001 in “Advances in protein chemistry” 5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
15 citations
,
January 2014 in “Dermatology” Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.